Vimseltinib elicited an ORR of 40% vs 0% of matching placebo in patients with tenosynovial giant cell tumor in the phase 3 MOTION trial.
Approval Alert | Vimseltinib in Tenosynovial Giant Cell Tumors
Advertisement
Advertisement
Trending on CancerNetwork
1
Why MRI Contrast Agents Are Not Interchangeable for Detecting Brain Metastases
2
FDA Gives Accelerated Approval to Sevabertinib in HER2+ NSCLC
3
Durvalumab Combo Improves Survival in First-Line Extensive-Stage SCLC
4
INBRX-106 Plus Pembrolizumab Nearly Doubles Response Rate in HNSCC
5